Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications
Cancer Immunotherapy Trials Biothera Pharmaceuticals Expands Relationship with Merck, Enters Collaboration for Combination Cancer Immunotherapy Trials in Multiple Indications Biothera’s Imprime PGG and Merck’s anti-PD-1 inhibitor KEYTRUDA® (pembrolizumab) to be evaluated in combination for patients with either advanced melanoma or metastatic triple negative breast cancer (TNBC) Under previous agreement, Big Ten Cancer Research Consortium (BTCRC) plans…
